Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer.

@article{Desideri2018BenefitOA,
  title={Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer.},
  author={Isacco Desideri and Giulio Francolini and Vieri Scotti and Donato Pezzulla and Carlotta Becherini and Francesca Terziani and Camilla Delli Paoli and Emanuela Olmetto and Luca Visani and Icro Meattini and Daniela Greto and Pierluigi Bonomo and Mauro Loi and Beatrice Detti and Lorenzo Livi},
  journal={Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},
  year={2018}
}
PURPOSE Here, we present the results from a retrospective analysis, with the purpose of evaluating the safety and feasibility of nivolumab and radiotherapy (RT) concomitant association in metastatic kidney and lung cancer patients. MATERIALS AND METHODS From August 2015 until September 2017, we retrospectively observed 20 patients with metastatic lung and renal cell carcinoma who had been initiated therapy with nivolumab and underwent concomitant RT. RT was administered either as an ablative… CONTINUE READING
BETA